TMO vs ABT Stock Comparison

Thermo Fisher Scientific and Abbott Laboratories Prices as of Nov 13, 2026 Peers: Industry group
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$187.98B
P/E
40.0x
Revenue (TTM)
$48.23B
Div. yield
2.32%
Medical Devices Healthcare
5 wins

Head to Head

12 decided of 12

Thermo Fisher Scientific leads on 7 of the 12 questions below (Thermo Fisher Scientific 7, Abbott Laboratories 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionTMOABTLeader
Larger companyMarket capitalisation $259.44B $187.98B TMO
Cheaper on earningsLower P/E, profitable companies only 36.6x 40.0x TMO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 27.0x 19.1x ABT
Faster revenue growthRevenue growth, trailing twelve months +8.3% +10.0% ABT
More profitableNet margin, trailing twelve months 14.9% 9.7% TMO
Better return on capitalReturn on invested capital 8.0% 5.7% TMO
Less leveragedLower net debt / EBITDA 3.1x 2.5x ABT
Higher dividend yieldTrailing dividend yield 0.26% 2.32% ABT
Better 1-year returnPrice return, last 12 months +20.7% -16.0% TMO
Better 5-year returnAnnualised price return, 5 years +2.0%/yr -3.3%/yr TMO
Less volatileAnnualised volatility, 1 year 30.7% 28.5% ABT
Higher overall scoreMean of the five percentile scores vs peers 60/100 56/100 TMO

Percentile Scorecard

TMOABT

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisTMOABT
Valuation 62 #94 of 243 74 #65 of 243
Growth 41 #136 of 228 26 #168 of 228
Profitability 82 #40 of 222 82 #41 of 222
Financial Health 31 #172 of 248 33 #167 of 248
Shareholder Returns 82 #29 of 158 65 #56 of 158
Overall 60 56
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • ABT ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodTMOABTSPY
1 month +4.0%+5.4% -2.0%
3 months +19.1%-2.4% -2.8%
6 months +59.7%+28.5% +2.0%
Year to date +20.8%-13.4% +10.6%
1 year +20.7%-16.0% +12.2%
3 years +52.5%+11.8% +68.1%
3 years, per year +15.1%+3.8% +18.9%
5 years +10.2%-15.5% +61.4%
5 years, per year +2.0%-3.3% +10.1%
10 years +362.9%+170.4% +248.5%
10 years, per year +16.6%+10.5% +13.3%

Risk

MeasureTMOABTSPY
Volatility, 1Y 30.7%28.5% 13.6%
Downside volatility, 1Y 29.2%27.8% 13.9%
Beta vs S&P 500, 1Y 0.710.07 1.00
Return / volatility, 1Y 0.67-0.56 0.90
Max drawdown, 5Y -41.5%-41.6% -25.4%
From 52-week high -3.0%-16.9% -3.2%
52-week high $721.63$130.59 $779.14
52-week low $438.34$82.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleTMOABT
P/E now vs peer median 36.6xmedian 26.5x 40.0xmedian 26.5x
P/S now vs peer median 5.5xmedian 2.7x 3.9xmedian 2.7x
EV/EBITDA now vs peer median 25.5xmedian 18.4x 20.3xmedian 18.4x
P/FCF now vs peer median 34.2xmedian 25.4x 27.8xmedian 25.4x
P/B now vs peer median 4.7xmedian 2.5x 3.6xmedian 2.5x
PEG now vs peer median 4.84median 0.98 -13.92median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsTMOABT
Revenue $47.35B $48.23B
Gross profit $19.45B $27.46B
Operating income $8.47B $6.65B
Net income $7.09B $4.70B
Free cash flow $7.60B $6.76B
R&D $1.40B $3.31B
EPS (diluted) $19.06 $2.70
Cash & equivalents $5.46B $4.05B
Total debt $41.37B $31.16B
Shares (diluted) 371.00M 1.74B
Enterprise value $236.08B $162.45B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricTMOABT
P/E 36.6x 40.0x
P/FCF 34.2x 27.8x
P/Operating cash flow 27.8x 21.2x
P/S 5.5x 3.9x
P/B 4.7x 3.6x
P/Tangible book 7.1x 5.9x
EV/EBITDA 25.5x 20.3x
EV/EBIT 34.8x 32.3x
EV/Revenue 6.2x 4.5x
EV/FCF 38.8x 31.8x
EV/Operating cash flow 31.6x 24.3x
PEG (3Y EPS CAGR) 4.84 -13.92

Growth

14 metrics
MetricTMOABT
Revenue growth (1Y) 8.3% 10.0%
Revenue CAGR (3Y) 2.9% 6.5%
Gross profit growth (1Y) 7.8% 12.1%
Gross profit CAGR (3Y) 4.0% 7.8%
Operating income growth (1Y) 12.8% -13.8%
Operating income CAGR (3Y) 7.2% 3.5%
Net income growth (1Y) 7.9% -66.4%
Net income CAGR (3Y) 6.2% -3.1%
EPS growth (1Y) 9.7% -66.1%
EPS CAGR (3Y) 7.6% -2.9%
Operating cash flow growth (1Y) 21.9% -2.9%
Operating cash flow CAGR (3Y) 4.5% 10.6%
Free cash flow growth (1Y) 24.3% -2.3%
Free cash flow CAGR (3Y) 5.1% 14.6%

Profitability

14 metrics
MetricTMOABT
Gross margin 41.1% 56.9%
EBITDA margin 24.4% 21.9%
Operating margin 17.9% 13.8%
Pretax margin 16.7% 13.6%
Net margin 14.9% 9.7%
FCF margin 16.0% 14.0%
Operating cash flow margin 19.7% 18.4%
Return on equity 13.2% 9.1%
Return on assets 6.2% 4.3%
Return on invested capital 8.0% 5.7%
Return on capital employed 8.5% 7.2%
Asset turnover 0.4x 0.4x
Cash conversion (OCF / net income) 1.3x 1.9x
Stock comp / revenue 0.7% 1.5%

Financial Health

11 metrics
MetricTMOABT
Debt / assets 36.2% 28.8%
Debt / equity 0.8x 0.6x
Net debt / EBITDA 3.1x 2.5x
Debt / FCF 5.4x 4.6x
Liabilities / assets 52.1% 52.3%
Equity / assets 47.9% 47.7%
Interest coverage 12.0x 6.7x
Current ratio 1.8x 1.5x
Quick ratio 1.2x 0.8x
Cash ratio 0.4x 0.3x
Altman Z-score 4.18 3.36

Shareholder Returns

7 metrics
MetricTMOABT
Dividend yield 0.3% 2.3%
Net buyback yield 1.6% 0.7%
Shareholder yield 1.8% 3.0%
Payout ratio (earnings) 9.5% 92.0%
Payout ratio (FCF) 8.9% 64.0%
Dividend growth (1Y) 8.0% 6.9%
Dividend CAGR (3Y) 10.1% 7.4%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusTMOABT
Forward P/E 27.0xFY2026 19.1xFY2026
EPS, next fiscal year $25.92FY2026 $5.69FY2026
EPS growth, next FY +13.3%FY2026 +10.5%FY2026
EPS growth, the year after +2.2% +10.2%
Revenue, next fiscal year $50.12BFY2026 $52.99BFY2026
Revenue growth, next FY +12.5%FY2026 +19.5%FY2026
Revenue growth, the year after -2.7% -2.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersTMOABT
Held by institutions 90.2% 79.2%
Institutions holding 2,627 2,983
Change in shares held, QoQ +0.8% +0.3%
Institutions buying 1,145 1,261
Institutions selling 1,145 1,379
Buyers to sellers 1.00 0.91

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

TMOABT
TMO 1.00 0.24
ABT 0.24 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, TMO and ABT?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Thermo Fisher Scientific (TMO) $259.44B, Abbott Laboratories (ABT) $187.98B.

Which stock is cheaper, TMO and ABT?

Thermo Fisher Scientific (TMO) trades on the lowest price-to-earnings ratio (Thermo Fisher Scientific (TMO) 36.6x, Abbott Laboratories (ABT) 40.0x). On next year's consensus earnings, Abbott Laboratories (ABT) is cheapest (Thermo Fisher Scientific (TMO) 27.0x, Abbott Laboratories (ABT) 19.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Abbott Laboratories (ABT) grew revenue fastest over the trailing twelve months: Thermo Fisher Scientific (TMO) +8.3%, Abbott Laboratories (ABT) +10.0%.

Which company is more profitable?

Thermo Fisher Scientific (TMO) has the highest net margin (Thermo Fisher Scientific (TMO) 14.9%, Abbott Laboratories (ABT) 9.7%). On return on invested capital, Thermo Fisher Scientific (TMO) leads (Thermo Fisher Scientific (TMO) 8.0%, Abbott Laboratories (ABT) 5.7%).

Which stock has performed better?

Over the past year Thermo Fisher Scientific (TMO) returned the most: Thermo Fisher Scientific (TMO) +20.7%, Abbott Laboratories (ABT) -16.0%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Thermo Fisher Scientific (TMO) +2.0%/yr, Abbott Laboratories (ABT) -3.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Abbott Laboratories (ABT) has the highest dividend yield: Thermo Fisher Scientific (TMO) 0.26%, Abbott Laboratories (ABT) 2.32%.

Which stock is riskier?

By one-year price volatility, Abbott Laboratories (ABT) has been the steadiest (Thermo Fisher Scientific (TMO) 30.7%, Abbott Laboratories (ABT) 28.5%). Volatility measures how widely the price swings, not the risk of the business.

Do TMO and ABT move together?

Their daily returns over the past year have a correlation of 0.24, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, TMO and ABT?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Thermo Fisher Scientific (TMO) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.